Mitsubishi Tanabe Records Additional ¥8.8 Billion For Hepatitis Compensation; President and VP Take Salary Cut
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Tanabe Pharma announced April 13 a ¥20 billion compensation plan for hepatitis C victims who were infected from tainted blood products manufactured by the company. Last year, Mitsubishi Tanabe set aside ¥11.2 billion for the compensation purpose as a special loss for the third fiscal quarter; the remaining ¥8.8 billion will be recorded as a special write-off for the fourth quarter. To take responsibility for the loss, both the company's president and a vice president will have their salaries reduced by 20 percent for three months, starting in April. (Click here for more - Japanese language
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.